You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Destiny Pharma’s novel antibiotic asset clears safety review

Brighton, UK-based Destiny Pharma has announced a positive interim safety review of its ongoing Phase IIb study of its lead antibiotic asset XF-73.